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Abstract
Objective
The main objective of this study was to compare disease burden in rheumatoid arthritis
(RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA).
Methods
In this cross-sectional study, all the RA (1093), PsA (365) and ax-SpA (333) patients who
visited the out-patient clinic of the Hospital of Southern Norway Trust during the year 2013
were included; the RA patients all had a RA diagnosis verified by the treating rheumatolo-
gist, the PsA patients all fulfilled the ClASsification for Psoriatic ARthritis (CASPAR) criteria
and the ax-SpA patients all fulfilled the Assessment of SpondyloArthritis international Socie-
ty (ASAS) classification criteria for ax-SpA. Patient-reported health status, demographic
variables, medications, and composite scores of disease activity were assessed. The main
analyses were performed using General Linear Models adjusted for age, sex and multiple
comparisons. Correlation analyses were performed using Spearman’s rho.
Results
The reported pain, joint pain, patient’s global assessment and fatigue were similar in PsA
and ax-SpA, but significantly lower in RA. The 28-joint Disease Activity Score (DAS28)
(0.3±0.1, p = 0.003), Clinical Disease Activity Index (CDAI) (1.0±0.4, p = 0.028) and Routine
Assessment of Patient Index Data 3 (RAPID3) (0.4±0.1, p = 0.004) were all significantly
higher in PsA vs. RA. RAPID3 showed moderate to high correlation with DAS28 (rho =
0.521, p<0.001) and CDAI (rho = 0.768, p<0.001) in RA and PsA, and with Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) (rho = 0.902, p<0.001) and Bath Ankylosing
Spondylitis Functional Index (BASFI) (0.865, p<0.001) in ax-SpA and PsA.
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Conclusion
In conclusion, patient- reported outcome measures were similar in our population of PsA
and ax-SpA patients, but significantly lower for the RA patients. Composite disease activity
measures were lower in RA than in PsA and ax-SpA, but the magnitude of these differences
was small and probably not of clinical significance. Our study indicates that disease burden
in RA, PsA and ax-SpA may be more similar than previously demonstrated.
Introduction
Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA) are
the most common inflammatory rheumatic diseases in ordinary outpatient clinics. In Norway
the prevalence reported is 0.5% for RA [1], 0.2% for PsA [2] and 0.2% for ankylosing spondyli-
tis (AS) [3]. These inflammatory disorders are characterised by different clinical, laboratory
and imaging hallmarks. RA is characterised by symmetric and erosive arthritis typically affect-
ing small and medium-sized joints [4]. PsA is a more heterogeneous inflammatory disease
which may present as mild monoarthritis or severe polyarthritis and may also involve the axial
skeleton and the entheses [5,6]. AS is a systemic inflammatory disorder that affects the sacroili-
ac joints and the spine, and can also affect peripheral joints and entheses [7]. Axial spondyloar-
thritis (ax-SpA) is a common term for inflammatory joint disorders with inflammation in axial
skeleton and may include AS, undifferentiated spondyloarthritis and PsA with axial involve-
ment [8,9]. In RA, bone involvement is characterized by erosions, whereas in PsA and ax-SpA
bone involvement also includes signs of bone new formation [4,10,11].
Major clinical improvements have over the last years been achieved in the outcome of in-
flammatory rheumatic diseases. This has been attributed to various factors [7,12–15]. For ex-
ample, better treatments are available and early aggressive treatment strategies have been more
commonly adopted, including the treat to target (T2T) strategy for both RA and SpA. In addi-
tion, there have been changes in environmental exposures, e.g. smoking habits, which also may
have altered outcome of inflammatory joint disorders.
Due to heterogeneity in expression of inflammatory rheumatic diseases, it is expected that
there may be differences in disease burden between RA, PsA and ax-SpA. Few studies have
compared clinical findings and patient- reported outcome measures in the three disease entities
RA, PsA and ax-SpA, although several studies have compared health-related quality of life in
these diseases [16–19].
Thus, the main objective of this study was to compare patient-reported health status and
composite scores of disease activity in unselected patient populations of RA, PsA and ax-SpA,
recruited from an ordinary out-patient clinic in Norway. Secondary objectives were to compare
demographics and the use of Disease-Modifying AntiRheumatic Drugs (DMARDs) in RA, PsA
and ax-SpA.
Methods
Study population
This is a cross-sectional study of consecutive RA, PsA and ax-SpA patients who visited the out-
patient clinic of the Hospital of Southern Norway Trust during the year 2013. The RA, PsA
and ax-SpA patients in the out-patient clinic were monitored by use of the GoTreatIT Rheuma
computer software system (www.diagraphit.com) as part of the ordinary clinical care. The RA
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patients (1093) all had a RA diagnosis verified by the treating rheumatologist, but were not
evaluated using the American College of Rheumatology (ACR) classification criteria on a regu-
lar basis [20]. 66.8% (682/1021) of the RA patients were rheumatoid factor (RF) positive,
69.4% (697/1004) anti-citrullinated peptide antibodies (ACPA) positive and 75.3% (747/992)
positive to RF, ACPA or both. The PsA patients (365) all fulfilled the ClASsification for Psori-
atic ARthritis (CASPAR) criteria [21]. PsA patients with axial inflammation were counted to
the ax-SpA group. Patients with AS (266), PsA with axial inflammatory affection (22) or non-
radiographic ax-SpA (45) were included in the ax-SpA group. They all (333) fulfilled the ASAS
classification criteria for ax-SpA [8]. 85.6% (n = 250/292) of the ax-SpA and 27.1% (n = 45/
166) of the PsA patients were HLA-B27 positive.
Data collection
Patients completed computerized questionnaires assessing health status and demographic vari-
ables. The demographic data included age, gender, weight, height, body mass index (BMI),
years of education, current smoking status and employment status.
Employment status was assessed and divided into 5 groups; Full-time employment, part-
time employment (including part- time work/ disabled pensioner, part-time work/ sick leave,
part-time work/ unemployed), disabled pensioner, not working for other reasons (including
medical/ occupational rehabilitation, maternity/ paternity leave, student, sick leave and unem-
ployed) and pensioner.
Patients’ global assessment, pain, joint pain, spine pain, spine pain at night and fatigue was
reported on a visual analogue scale (VAS, 0–100 mm). Morning stiffness was reported in hours
(0–6). Patients’ physical function was assessed by the Modified Health Assessment Question-
naire (MHAQ, 0–3) [22]. For calculation of the Routine Assessment of Patient Index Data 3
(RAPID3, 0–10) we used pain, patient’s global assessment and MHAQ, as MHAQ and not
MDHAQ was assessed in the outpatient clinic [23]. Disease activity in ax-SpA and PsA was
also evaluated by employing the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI,
0–10) and the Bath Ankylosing Spondylitis Functional Index (BASFI, 0–10) [24,25].
C-reactive protein (CRP) (turbidimetry, lowest detectable value 1 mg/L) and erythrocyte
sedimentation rate (ESR, mm/hr) (Westergren’s method) were measured. 28-swollen (28-SJC)
and tender (28-TJC) joint count were performed by a rheumatologist or a specially trained
nurse, who also assessed evaluator’s global assessment (VAS, 0–100 mm). The Clinical Disease
Activity Index (CDAI) and 28-joint Disease Activity Score (DAS28-ESR) with (DAS28-ESR
(4)) and without (DAS28-ESR(3)) patient’s global assessment was calculated by the computer
system [26,27].
We retrieved data on current and previous use of conventional synthetic DMARDs
(csDMARDs), biologic DMARDs (bDMARDs) and prednisolon/ prednisone.
Statistics
Statistical analyses were performed using SPSS version 16.0 (SPSS Inc, Chicago, IL, USA).
We performed descriptive analyses of the crude estimates. The threshold for significance
was set at p<0.05. Data for continuous demographics were analysed using One-way ANOVA
with post-hoc tests (Tukey HSD when homogeneity of variance, Dunnett’s T3 when violation
of homogeneity of variances). Data for categorical demographics and medication were analysed
using Pearson Chi-Square test for independence. The main analyses were performed using a
General Linear Model with adjustments for age and sex. The different patient-reported out-
come measures, composite scores, ESR and CRP were used as the dependent variable in the
General Linear Model. Sex and diagnoses were put as fixed factors and age as a covariate factor.
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Pairwise comparisons between the RA, PsA and ax-SpA groups were performed using Bonfer-
roni adjustment for multiple comparisons. The unadjusted analyses were performed by use of
One-way ANOVA with post-hoc tests (Tukey HSD when homogeneity of variance, Dunnett’s
T3 when violation of homogeneity of variances) or independent t-test as appropriate. Correla-
tion between RAPID3 and DAS28, CDAI, BASDAI and BASFI were investigated using
Spearman’s rho.
Ethics Board Approval
This study has been approved by the Norwegian Regional Committees for Medical and Health
Research Ethics (Regional komité for medisinsk og helsefaglig forskningsetikk Midt-Norge
2010/3078) as a quality assurance study of established treatment with data obtained from the
hospital medical record systems. The data were anonymized prior to analysis. Patient consent
was not required according to Norwegian law, and confirmed by the Norwegian Regional
Committees for Medical and Health Research Ethics.
Results
Study population
S1 Table displays the demographic characteristics of the study population of 1093 RA, 365 PsA
and 333 ax-SpA patients. The ax-SpA patients (48±12.9 years) were significantly (p<0.001)
younger than the PsA (55±12.4 years) and the RA patients (63±13.8 years).
Although the RA patients were older than the ax-SpA patients, the two groups did not differ
in disease duration (RA: 12.4±10.6 years, ax-SpA: 13.0±11.8 years, p = 0.777). The PsA patients
had significantly (p<0.001) shorter disease duration (9.9 ± 8.2) than the RA and the ax-SpA
patients. The RA patients had significantly (p<0.001) less education (11.4±3.6 years) than the
PsA (12.4±3.6 years) and the ax-SpA patients (12.8±3.5 years).
The RA patients were predominantly female (68.5%), the ax-SpA patients predominantly
male (66.7%), whereas the gender distribution in the PsA group was equally balanced with
49.3% female. There was no statistically significant difference in smoking habits between the
diagnosis groups.
In the RA group a higher percentage of the patients were pensioners (41.4%) compared to
the PsA (16.7%) and the ax-SpA (7.4%) group. When considering only the working age group,
there was still a highly significant difference in employment status between the RA, PsA and
ax-SpA group; 26.0% of the RA patients, 32.0% of the PsA patients and 44.3% of the ax-SpA
patients had full-time employment. The highest proportion of disabled pensioners was found
in the RA group (38.7%).
The PsA patients had significantly higher BMI (27.6±4.3 kg/m2) than the RA (25.7±5.4 kg/m2,
p<0.001) and the ax-SpA (26.4±4.3 kg/m2, p = 0.002) patients; also when adjusted for age and
gender.
Patient reported outcome measures and laboratory assessments
S2 Table shows patient-reported outcome measures and laboratory measures, both unad-
justed values and values adjusted for sex and age. In the adjusted analysis patient’s mean
global assessment was significantly (p<0.001) lower for RA patients (31.7±0.9 mm) than
for PsA (39.2±1.4 mm) and ax-SpA (41.0±1.6 mm) patients, whereas no significant differ-
ence was found for evaluator’s global assessment between the diagnosis groups. RA patients
also reported significantly less pain (31.2±0.9 mm) than the PsA (35.8±1.4 mm) and the
ax-SpA (39.0±1.5 mm) patients (p = 0.015). Similar results were also seen for joint pain
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(RA: 29.6±0.8 mm, PsA: 35.6±1.3 mm, ax-SpA: 38.4 ± 1.5 mm). RA patients also experienced
significantly less fatigue (34.3±1.0) than the PsA (44.3±1.6) and the ax-SpA (46.8±1.8) patients
(p<0.001).
Further, the ax-SpA patients reported significantly more spine pain and spine pain at night
than the RA and the PsA patients. In terms of patients’ global evaluation, pain, joint pain and
fatigue, the PsA patients had similar values to the ax-SpA patients, while the RA patients had
significantly lower values. These differences in patient reported outcome measures were still
significant when adjusted for current use of bDMARDs, steroids and disease duration.
There was no significant difference in morning stiffness, ESR, CRP or MHAQ between the
RA, PsA and ax-SpA groups. BASDAI (0.5 ± 0.2, p = 0.009) and BASFI (0.4 ± 0.1, p = 0.030)
were significantly higher in the ax-SpA group than in the PsA group.
Supplementary subgroup analyses of patient-reported outcome measures and laboratory
measures were performed for only seropositive RA patients compared to PsA and ax-SpA pa-
tients. This did not change the main outcomes (S3 Table).
Composite scores
In the sex and age adjusted analyses, DAS28-ESR(4) was significantly (p = 0.003) lower for the
RA patients (2.59±0.04) than for the PsA patients (2.85±0.07). The CDAI results were similar to
the DAS28-ESR(4): 6.08±1.5 in the RA group, 7.03±0.4 in the PsA group, p = 0.028 (S4 Table).
This despite the fact that PsA patients (0.51±0.1), were found to have significantly (p = 0.016)
lower 28-SJC than the RA patients (0.79±0.1). There was no significant (0.42, p = 0.053) difference
in 28-TJC between the PsA and RA patients. RAPID 3 was significantly lower in RA (2.5±0.1)
than in PsA (2.9±0.1, p = 0.004) and ax-SpA patients (3.1±0.1, p<0.001). RAPID3 showed mod-
erate correlation with DAS28-ESR(4) (rho = 0.521, p<0.001) and CDAI (rho = 0.768, p<0.001)
for the RA and the PsA patients. RAPID3 was also strongly correlated to BASDAI (rho = 0.902,
p<0.001) and BASFI (0.865, p<0.001) for the ax-SpA and PsA patients.
Subgroup analyses of CDAI, TJC28, SJC28, DAS28-ESR(3) and DAS28-ESR(4) were also
performed, including only seropositive RA patients compared to PsA and ax-SpA patients.
These subgroup analyses did not affect the main outcomes, except for DAS28-ESR(3), for
which the mean difference between the RA and the PsA patients went from 0.17, p = 0.046 to
0.09, p = 0.312. For DAS28-ESR(4) the mean difference between the RA and the PsA patients
went from 0.26, p = 0.003 to 0.20, p = 0.036 (S5 Table).
Treatment
S6 Table shows current and previous use of bDMARDs and csDMARDs. The current use of
bDMARDs was significantly more frequent (p = 0.001) in the ax-SpA (45.3%), than in the PsA
(33.4%) and the RA group (34.5%). Former use of bDMARDs was also more frequent
(p = 0.002) in the ax-SpA (53.8%) than in the PsA (41.4%) and the RA group (44.4%). The cur-
rent use of TNF inhibitors was 45.0% in the ax-SpA, 31.8% in the PsA and 21.0% in the RA
group. Previous and current use of csDMARDs was more frequent in the RA group compared
to the PsA group (previous use: 92.1% versus 84.4%, p<0.001, current use: 61.1% versus 52.9%,
p = 0.003).
Discussion
The main finding in this study is that the PsA and the ax-SpA patients reported more pain and
fatigue than the RA patients. Interestingly, the reported pain, joint pain, patient’s global assess-
ment and fatigue were similar for the PsA and the ax-SpA patients, but significantly lower for
the RA patients. Further, the composite disease activity measures DAS28, CDAI and RAPID3
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were higher in PsA than in RA, but the magnitude of these differences was small and probably
not of clinical significance.
Our study provided a unique opportunity to compare the disease burden in RA, PsA and
ax-SpA. There are a limited number of studies comparing these disease entities, and only few
of them compare disease burden [16–19]. Zink et al compared quality of life and treatment
among patients with RA, PsA and AS and reported a comparable burden of illness [16]. Similar
disease activity, disability and reduced quality of life in patients with PsA compared to RA are
previously reported [28–30]. To our knowledge this is one of the first large-scale studies in
Scandinavia comparing patient-reported outcome measures and disease activity measures of
consecutive RA, PsA and ax-SpA patients from an out-patient clinic.
Measuring patient perception of health is considered as a standard approach, not only in
controlled clinical trials and observational longitudinal studies, but also in clinical practice
[31–33]. Interestingly, from the patient perspective, pain is the area of health in which patients
have their highest priorities for improvement [31]. This highlights the importance of improv-
ing our efforts to reduce pain in patients with inflammatory joint disorders.
The comparison of health status of patients with different inflammatory rheumatic disease
entities may be challenging because of the different age and sex distributions and the different
disease durations of these disorders. As expected, in our study the RA patients were older and
predominantly female, while the ax-SpA patients were younger and predominantly male. Fur-
ther, the PsA patients had significantly shorter disease duration than the RA and the ax-SpA
patients. Sex differences in pain scores in inflammatory arthritis, with higher pain levels in fe-
males, have previously been reported [34]. As shown in S2 and S4 Tables, the adjusting for age
and sex in the analyses implied major differences in significance when comparing some of the
outcome variables between the diagnosis groups. There were e.g. significant differences in pain,
joint pain and RAPID3 scores between the RA, PsA and ax-SpA patients when analyses were
adjusted for age and sex, but not in the unadjusted analyses. Adjustment for disease duration
and current use of bDMARDs and steroids did not change the outcomes.
Considering only the working age group, there were significant (p<0.001) differences in
employment status; 44.3% of the ax-SpA, 32.0% of the PsA and 26.0% of the RA patients had
full-time employment. A higher percentage of the RA patients (38.7%), than the PsA (28.7%)
and the ax-SpA (17.3%) patients were disabled pensioners. In comparison, 9.4% of the general
population in Norway were disabled pensioners in 2013 [35].
This is interesting, as the RA patients demonstrated significantly lower global assessment,
pain, spine pain, spine pain at night, joint pain and fatigue than the PsA and the ax-SpA pa-
tients, values adjusted for age and gender. Louie et al compared functional limitations in RA
and AS patients with uncertain results [36]. A similar overall malignancy incidence between
RA and PsA patients has been described [37]. In a recent study RA, but not PsA patients, were
found to have elevated risk of mortality compared to the general population [38]. A recent sys-
tematic review by Jamnitski et al. concluded that the cardiovascular risks were comparable in
RA and PsA [39]. PsA has also been reported to be associated with higher rates of obesity, dia-
betes and hypertrigylceridemia compared with RA [40]. The PsA patients in this study dis-
played significantly higher BMI than the RA or the ax-SpA patients. Similar differences in BMI
between PsA and RA patients have also previously been reported [40–42].
When the composite score RAPID3 was evaluated, the RA patients were found to have lower
disease activity than the PsA and the ax-SpA patients. In our clinical practice, patients complete
MHAQ (8 questions, a-h) and not MDHAQ (10 questions, a-j; question i: walking two miles,
question j: participate in sports). Using MHAQ as a surrogate marker for MDHAQ in the
RAPID3 calculations may at most contribute to an error in the final RAPID3 score (0–10) of 0.7.
This limitation was, however, equal for the RA, PsA and ax-SpA patients.
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The RA patients were also found to have lower disease activity than the PsA patients upon
evaluation of DAS28-ESR(4) and CDAI. Upon evaluation of DAS28-ESR(3) the difference be-
tween the RA and the PsA patients was smaller. This reflects the fact that DAS28-ESR(3) ex-
cludes patients’ global assessment of disease activity, a measure that in this study was
significantly lower for the RA than for the PsA patients.
DAS28 and CDAI scores are formally validated for RA [26,27], but not for PsA. However,
DAS28 has been used in randomised clinical trials for assessment of disease activity in PsA
[43,44]. In a busy clinical setting, DAS28 and CDAI appear attractive for evaluation of disease
activity also in PsA, and are on a regular basis assessed for the PsA patients in our clinic.
RAPID3 correlated significantly with DAS28-ESR(4) (rho = 0.521, p<0.001) and CDAI
(rho = 0.768, p<0.001). MHAQ did not differ significantly between the RA, PsA or ax-SpA
groups. Hence in our population, the differences demonstrated for the RAPID3 score in the
RA, PsA and ax-SpA groups are probably based on documented lower scores for patient’s as-
sessment of pain and patient’s global assessment of health in the RA group.
Interestingly, although developed for RA, and ostensibly more focused on peripheral joints,
the RAPID3 has been suggested to correlate well with BASDAI in AS patients [45]. In this
study RAPID3 was also found to be strongly correlated with BASDAI (rho = 0.902, p<0.001)
and BASFI (0.865, p<0.001) for the ax-SpA and PsA patients.
Remarkably, a higher proportion of the ax-SpA (45.3%) than the RA (34.5%) and the PsA
(33.4%) patients were currently using bDMARDs (p = 0.001). The same trend was seen for for-
mer use of bDMARDs (ax-SpA: 53.8%, PsA 41.4%, RA 44.4%, p = 0.002) [46]. Possible reasons
for this may be the younger age of the ax-SpA patients and socio-economical considerations;
sufficient disease control may contribute to maintain work ability. Further, the effect of
csDMARDs in ax-SpA is controversial; csDMARDs are not routinely prescribed for patients
with only axial disease as they have not shown to be efficacious [47–49]. Interestingly, the RA
patients used significantly more steroids than the PsA and the ax-SpA patients. Adjustment for
current use of bDMARDs and steroids in the main analyses did not change the outcomes.
The use of a large routine database of unselected patients seen in ordinary rheumatology
outpatient clinic allowed a unique opportunity of direct comparison between RA, PsA and ax-
SpA patients. One limitation in our study is, however, the varying amount of missing data, as
reported in S1–S5 Tables. Another limitation of this study is that the 1093 RA patients with
clinical RA diagnosis had not been systematically evaluated for the ACR classification criteria.
This is a limitation in interpreting the results, as patients who do not meet the ACR criteria
may have a milder disease and better quality of life. However, as many as 75.3% of our RA pa-
tients were positive to RF, ACPA or both. In comparison, a review article from 2010 reported
50–80% of RA patients to be positive for RF, ACPA or both [4]. Subgroup analyses of the sero-
positive RA patients compared to the PsA and the ax-SpA patients did not change the main
outcomes, except for DAS28-ESR(3), where the mean difference between the RA and the PsA
patients went from 0.17, p = 0.046 to 0.09, p = 0.312. For DAS28-ESR(4) the mean difference
between the RA and the PsA patients went from 0.26, p = 0.003 to 0.20, p = 0.036. The sub-
group analyses are listed in S3 and S5 Tables. A further limitation of the study is that the out-
come measures of employment and subjective disease activity measures may be confounded by
multiple factors, e.g. coexisting medical conditions or social factors not evaluated in this study.
The differences in patient-reported outcome measures and disease activity between the RA
and PsA patients in our study may have different explanations. In recent years, studies have
shown differences in inflammatory processes involved in RA, PsA and ax-SpA [50]. Pain
mechanisms in RA and PsA may be different, as the inflammatory process in PsA frequently
involves entheses and spine [5]. Unfortunately, we did not have measures for entheses involve-
ment, e.g. the MASES score, performed as routine care. Further, due to the rather frequent
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involvement of the DIP joints in PsA, the use of 28 joint count instead of e.g. the 66/68 joint
count may have underreported clinical inflammatory joint involvement in PsA.
In conclusion, patient reported outcome measures were similar in our population of PsA
and ax-SpA patients, but significantly lower for the RA patients. Composite disease activity
measures were lower in RA than in PsA and ax-SpA, but the magnitude of these differences
was small and probably not of clinical significance. Our study indicates that disease burden in
RA, PsA and ax-SpA may be more similar than previously demonstrated.
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